Table 2.

OS, DFS and DDFS by HER2 expression level and genomic risk.^a.

HER2 Status, Genomic Risk		Estimated 10-year OS (95% CI)	OS HR, 95% CI, p value	Estimated 10-year DFS (95% CI)	DFS HR, 95% CI, p value	Estimated 10-year DDFS (95% CI)	DDFS HR, 95% CI, p value
All population	HER2-0	88% (0.83–0.91)	0.66 (0.4–1.08), P = 0.10	82% (0.77–0.86)	0.72 (0.49–1.06) P = 0.09	85% (0.8–0.88)	0.71 (0.45–1.1) P = 0.13
	n = 304
	HER2-low	91% (0.87–0.94)		87% (0.83–0.90)		90% (0.85–0.92)
	n = 304
Low Genomic Risk Oncotype RS ≤ 25	HER2-0	92% (0.88–0.95)	0.91 (0.5–1.67) P = 0.77	87% (0.82–0.91)	0.89 (0.55–1.42), P = 0.65	90% (0.86–0.93)	1.05 (0.61–1.79) P = 0.85
	n = 252
	HER2-low	92% (0.87–0.95)		88% (0.84–0.92)		90% (0.85–0.93)
	n = 245
High Genomic Risk Oncotype RS ≥ 26	HER2-0	68% (0.53–0.80)	0.30 (0.11–0.78) P = 0.01	59% (0.43–0.71)	0.4 (0.2–0.82), P = 0.01	59% (0.43–0.71)	0.26 (0.11–0.63) P = 0.002
	n = 52
	HER2-low	89% (0.78–0.95)		81% (0.68–0.89)		89% (0.78–0.95)
	n = 59

Abbreviations: CI – confidence interval, DFS – disease free survival, DDFS – distant disease-free survival, HR – hazard ratio, OS – overall survival, RS – recurrence score.

^aOS, DFS and DDFS rates were calculated by the Kaplan–Meier method with the long-rank test, HR and associated 95% CI were analyzed using a Cox proportional hazards regression model.